Multidrug resistance in Aspergillus fumigatus [6]

New England Journal of Medicine

Volumn 347, Issue 26, 2002, Pages 2173-2174

  Warris, Adilia ^a   Weemaes, Corry M ^a   Verweij, Paul E ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; GAMMA INTERFERON; ITRACONAZOLE; POSACONAZOLE; PYRROLE DERIVATIVE; RAVUCONAZOLE; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ASPERGILLUS FUMIGATUS; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG STRUCTURE; FUNGICIDAL ACTIVITY; HUMAN; LETTER; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOSIS; NONHUMAN; PRIORITY JOURNAL;

EID: 0037180790     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200212263472618     Document Type: Letter

References (5)

1. Mosquera J, Denning DW. Azole cross-resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 2002;46:556-7.
2. van't Hek LG, Verweij PE, Weemaes CM, van Dalen R, Yntema JB, Meis JF. Successful treatment with voriconazole ofinvasive aspergillosis in chronic granulomatous disease. Am J Respir Crit Care Med 1998;157:1694-6.
3. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Conidium-forming Filamentous Fungi. Wayne, Pa.: National Committee for Clinical Laboratory Standards, 1998:4-7. (NCCLS document no. M38-P.)
4. Manavathu EK, Cutright JL, Loebenberg D, Chandrasekar PH. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of AspergiUus spp. to amphotericin B, itraconazole, voriconazole, and posaconazole (SCH 56592). J Antimicrob Chemother 2000;46:229-34.
5. Dannaoui E, Borel E, Monier M-F, Piens M-A, Picot S, Persat F. Acquired itraconazole resistance in Aspergillus fumigatus. J Antimicrob Chemother 2001;47:333-40.